Press Releases

November 5, 2026
Delivered total revenue of $24.0 million, an increase of 10% year over year Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24% Maintained an 81% gross margin, improved Net loss and Adjusted EBITDA loss by 8% and 16%, respectively Revises full-year 2026 revenue
November 4, 2026
LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming investor conferences: UBS Global Healthcare Conference Fireside chat and 1x1
September 3, 2026
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences: Lake Street Capital Markets’ 10 th Annual Best Ideas Growth